Rezolute appoints Sunil Karnawat as CCO; grants 275K inducement options

Rezolute, Inc.

Sunil Karnawat appointed Chief Commercial Officer effective Aug 18, 2025; brings 25+ years experience including four ultra-rare disease launches at Ultragenyx.
Employment agreement: base salary $475K, annual target bonus 40%, signing bonus $65K, plus 270K stock options and 25K RSUs vesting over time.
Inducement grant of 275K stock options at $6.55/share (closing price Aug 18); vesting: 25% on first anniversary, then 36 monthly installments, accelerated upon change of control.
Karnawat will lead launch strategy and global market readiness for ersodetug, a Phase 3 therapy for congenital and tumor hyperinsulinism.

item 1.01item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.